Cancer biotech upstart grabs $18M round, sets out to master relapsed prostate cancer
UC San Francisco researcher Bin Liu has spent years in the lab studying how to tackle prostate cancer cells. Recently, he’s been making progress on a new receptor target that he believes can come into play as patients start to become resistant to the new therapies that have hit the market. And now, Jay Lichter and his crew at Avalon Ventures in San Diego are adding a startup to the portfolio that will set out to make it a new drug for the field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
